About 22 results found for searched term "FEN1-IN-1" (0.124 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M14701 | FEN1-IN-1 | Others |
| FEN1-IN-1 (compound 1) is a flap endonuclease 1 (FEN1) inhibitor. FEN1-IN-1 binds to the active site of FEN1 and partly achieves inhibition by the co-ordination of Mg2+ ions. | ||
| M29227 | FEN1-IN-SC13 | Others |
| FEN1-IN-SC13 is a potent DNA fragmentation endonuclease 1 (FEN1) inhibitor (CN106692155A, SC13). | ||
| M2328 | Pirfenidone | TGF-beta/Smad |
| AMR69; S-7701 | ||
| Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone inhibits TGF-β bioactivity by affecting TGF-β2 mRNA expression and processing of pro-TGF-β in CCL-64 cells. Pirfenidone (AMR69) attenuates CCL2 and CCL12 production in fibrocyte cells. | ||
| M3026 | Sorafenib (BAY 43-9006) | Raf |
| BAY 43-9006 | ||
| Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively. Sorafenib is a multikinase inhibitor with IC50 values of 15 nM, 20 nM, 57 nM and 58 nM for VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib is a ferroptosis activator. | ||
| M3362 | Tolfenamic Acid | COX |
| GEA 6414 | ||
| Tolfenamic Acid is a COX-2 inhibitor, selectively inhibits COX-2, with an IC50 of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1. | ||
| M5046 | Imidafenacin (ONO-8025) | AChR/AChE |
| KRP-197; ONO-8025 | ||
| Imidafenacin (ONO-8025) is a urinary antispasmodic of the anticholinergic class.Imidafenacin(KRP-197; ONO-8025) is a potent and selective inhibitor of M3 receptors with Kb of 0.317 nM; less potent for M2 receptors (IC50=4.13 nM). | ||
| M5239 | Batefenterol | Adrenergic Receptor |
| GSK961081; TD-5959 | ||
| Batefenterol (GSK961081;TD-5959) is a novel muscarinic receptor antagonist and β2-adrenoceptor agonist; displays high affinity for hM2, hM3 muscarinic and hβ2-adrenoceptor with Ki values of 1.4, 1.3 and 3.7 nM, respectively. | ||
| M11331 | UC2288 | Mdm2 |
| UC2288 is a novel p21 attenuator with cellular permeability and oral activity (relatively selective activity for P21), based on the structural synthesis of sorafenib. UC2288 down-regulated the expression of P21 mRNA and reduced the level of P21 protein independently of p53, and had little effect on the stability of P21 protein. UC2288 did not inhibit VEGFR2 and Raf kinases, even at 10 μM. | ||
| M20678 | Belvarafenib | Raf |
| GDC5573; HM95573; RG6185 | ||
| Belvarafenib (GDC5573, HM95573, RG6185) is a selective and orally bioavailable pan-RAF kinase inhibitor with IC50 values of 41 nM, 7 nM and 2 nM for BRAF WT, BRAF(V600E) and CRAF kinases, respectively. | ||
| M20777 | GSK5182 | Estrogen Receptor |
| GSK5182 is a 4-Hydroxytamoxifen analog and a highly potent, selective, orally active estrogen-related receptor gamma (ERRγ) inverse agonist with an IC50 value of 79 nM.GSK5182 does not interact with other nuclear receptors, including ERRα and ERα. In addition, GSK5182 inhibits proinflammatory cytokine-induced catabolic factors and increases ROS production in liver cancer cells. cytokine-induced catabolic factors and increased ROS production in hepatocellular carcinoma cells. | ||
| M20790 | S-(+)-Ketoprofen | COX |
| Actron, (S)-Ketoprofen, Dexketoprofen | ||
| S-(+)-Ketoprofen (Compound 1, Actron, (S)-Ketoprofen, Dexketoprofen) is a potent inhibitor of cyclooxygenase (COX) with IC50 of 1.9 nM and 27 nM for COX-1 and COX-2, respectively. | ||
| M21513 | Vemurafenib-d7 | Raf |
| PLX4032-d7; RG7204-d7; RO5185426-d7 | ||
| Vemurafenib (PLX4032; RG7204; RO5185426) is a first-in-class selective B-RAF inhibitor that inhibits the activity of RAFV600E and c-RAF-1 with IC50 at 31 nM and 48 nM, respectively. Vemurafenib can induce autophagy. | ||
| M21520 | Vemurafenib-d5 | Raf |
| Vemurafenib (PLX4032; RG7204; RO5185426) is a first-in-class selective B-RAF inhibitor that inhibits the activity of RAFV600E and c-RAF-1 with IC50 at 31 nM and 48 nM, respectively. | ||
| M25246 | Naptumomab estafenatox | Others |
| ABR-217620; ANYARA | ||
| Naptumomab estafenatox (ABR-217620) is a tumor targeting superantigen (TTS). Naptumomab estafenatox is a fusion protein containing an anti-5T4 antibody and a SEA/E-120 superantige. Naptumomab estafenatox can be used for the research of lung cancer. | ||
| M29951 | Ketotifen | Metabolite/Endogenous Metabolite |
| HC 20-511 | ||
| Ketotifen (HC 20-511) is an orally active second-generation noncompetitive histamine 1 (H1) receptor blocker and mast cell stabilizer. Ketotifen can block 6-phosphogluconate dehydrogenase (PGD) in vitro. Ketotifen also has antiviral activity against SARS-CoV-2 and Influenza virus. Ketotifen can be used to the research of autoimmune encephalomyelitis (EAE) and asthma attack prevention. | ||
| M30200 | Fenspiride | Histamine Receptor |
| Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC50 values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases. | ||
| M30876 | Rovafovir etalafenamide | Reverse Transcriptase |
| GS-9131 | ||
| Rovafovir etalafenamide (GS-9131), a proagent of the adenosine nucleotide analogue GS-9148, is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Rovafovir etalafenamide is potent and active against a variety of NRTI mutants, and shows potent anti-HIV-1 activity. | ||
| M31246 | Tesofensine | Dopamine Transporter |
| Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM). | ||
| M45333 | FLTX1 | Estrogen Receptor |
| FLTX1 is a fluorescent tamoxifen derivative that specifically labels intracellular tamoxifen binding sites (estrogen receptors) under permeabilizing and non-permeabilizing conditions. In addition, FLTX1 exhibits potent anti-estrogenic activity of Tamoxifen in breast cancer cells.FLTX1 lacks estrogenic agonism in the uterus. | ||
| M53628 | Defensin HNP 4 | Antibiotic |
| Defensin HNP 4 (HNP 4) is a single 11 amino acid long fragment of HNP-41-11. | ||
| M56355 | FEN1-IN-4 | Others |
| FEN1-IN-4 is a human flap endonuclease-1 (hFEN1) inhibitor. | ||
| M56346 | Ibuprofen sodium | COX |
| Ibuprofen ((±)-Ibuprofen) sodium is an orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
